Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

7 results
Display

Pancreaticoduodenectomy with combined hepatic artery and portal vein resection after laparoscopic division of pancreaticosplenic ligament due to FOLFIRINOX-induced hepatic toxicity related secondary hypersplenism

Kim JS, Park JY, Choi M, Joo DJ, Hwang HK, Lee WJ, Kang CM

Pancreatic cancer is one of the dismal malignant disease in gastrointestinal tract. However, since the recent literature reporting median survival of FOLFIRINOX (leucovorin clcium, fluorouracil, irinotecan hydrochloride, oxaliplatin) chemotherapy was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX

Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW

Background/Aims: There has been growing evidence on the utility of neoadjuvant FOLFIRINOX in borderline resectable (BR) or locally advanced (LA) pancreatic cancer. However, factors predicting survival in these patients remain...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Extended distal pancreatectomy with thoracic wall resection after neoadjuvant FOLFIRINOX: Is there a limit of resection for pancreatic cancer after downstaging?

Giuliani T, López Rubio M, Montalvá Oron E, Maupoey Ibañez J, Boscá Robledo A, López Valdivia C, Pérez Rojas J, Lopez Andujar R

Indications and outcomes of extended pancreatectomies have been recently appraised by the International Study Group for Pancreatic Surgery. However, no definitive conclusions have been drawn, particularly in the setting of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adjuvant Therapy of Pancreatic Cancer

Paik WH

Pancreatic cancer is a lethal disease since curative resection is available in only 20% of patients at the initial diagnosis. Even after radical resection of the cancer, most patients experience...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis

Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C

BRCA gene mutations are found in up to 10% of pancreatic adenocarcinoma cases. We present a description of 4 cases along with a review of the current literature regarding pathogenesis,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Unresectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgical Resection

Huh G, Chun JW, You MS, Paik WH, Lee SH, Kim YT, Ryu JK

We report two cases of patients with unresectable pancreatic cancer treated with neoadjuvant chemotherapy and surgical resection. In the first case, main mass was located at the neck of the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer

Lee KH

Prognosis of pancreatic ductal adenocarcinoma is exceptionally poor because timely diagnosis in resectable stages is rare and there is no curative treatment for unresectable cases. Numerous researches to overcome these...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr